(24/7 MARKET NEWS) – Qualigen Therapeutics, Inc. (NASDAQ: QLGN) stated, this morning, that the United States Patent and Trademarks Office (USPTO) granted the Company patent number 11,560,380 for QN-302, its lead oncology investigational drug candidate, a small molecule selective transcription inhibitor with strong binding affinity to G4 complexes prevalent in cancer cells being investigated for solid tumors, including pancreatic cancer.
Qualigen Therapeutics is trading at $1.24, up $0.26 (+26.53%), on 570 thousand premarket shares.
Its 52-week trading range is $0.98 to $15.20. It’s trading above most of its recent key resistance levels and is now set up to challenge its March 7 trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
